Abstract
Recent years have seen an increase in the number of studies focusing on alkaline phosphatases (APs), revealing an expanding complexity of function of these enzymes. Of the four human AP (hAP) proteins, most is known about tissue non-specific AP (TNAP) and intestinal AP (IAP). This review highlights current understanding of TNAP and IAP in relation to human health and disease. TNAP plays a role in multiple processes, including bone mineralization, vitamin B6 metabolism, and neurogenesis, is the genetic cause of hypophosphatasia, influences inflammation through regulation of purinergic signaling, and has been implicated in Alzheimer’s disease. IAP regulates fatty acid absorption and has been implicated in the regulation of diet-induced obesity and metabolic syndrome. IAP and TNAP can dephosphorylate bacterial-derived lipopolysaccharide, and IAP has been identified as a potential regulator of the composition of the intestinal microbiome, an evolutionarily conserved function. Endogenous and recombinant bovine APs and recombinant hAPs are currently being explored for their potential as pharmacological agents to treat AP-associated diseases and mitigate multiple sources of inflammation. Continued research on these versatile proteins will undoubtedly provide insight into human pathophysiology, biochemistry, and the human holobiont.
Introduction
Alkaline phosphatases (APs) belong to a superfamily of proteins (EC 3.1.3.1) sharing conservation of metal binding sites, amino acids required for activity, and predicted fold structure (1). APs are used extensively in life sciences education, as a tool in molecular biology research and as a blood serum marker for liver and bone health, and yet we know surprisingly little about the potential these proteins have to influence our health. In general, APs are anchored to outside surface of the plasma membrane and catalyze the hydrolysis of phosphate groups from a variety of different substrates (dephosphorylation) in an alkaline environment, freeing inorganic phosphate (Pi) (2–4). APs are ubiquitous, with members of the AP super family of proteins extending from the archaea (5) to humans (2). Their ubiquity across life and their expansion and subsequent dynamic evolution in vertebrates implies both variety and conservation of function (6, 7). There are four genes encoding APs in humans. Three genes, ALPI, ALPP, and ALPPL2, display tissue-specific expression (TSAP proteins), whereas the fourth, ALPL is tissue non-specific in expression [tissue non-specific AP (TNAP) proteins] (Table 1). Unlike tissue distribution, surprisingly less is known about the function of these proteins, especially ALPP and ALPPL2 (Table 1). This mini-review will briefly highlight current knowledge of TNAP and intestinal AP (IAP) function in human health and disease (see Figure 1 for summary).
Table 1
| AP gene | AP protein | Tissue distribution | Known function |
|---|---|---|---|
| ALPL | Tissue non-specific AP | Liver, kidney, skeletal tissue, nervous system | Bone and tooth deposition |
| ALPP | PLAPb | Syncytiotrophoblasts, reproductive tumors | Unknown |
| ALPPL2 | GCAPb | Testis, reproductive tumors | Unknown |
| ALPI | IAPb | Intestine, enterocyte | Fatty acid absorption, lipopolysaccharide detoxification |
Description of human alkaline phosphatases (APs).a
Figure 1
Tissue Non-Specific AP
The most direct link between APs and human disease is hypophosphatasia (HPP), a disease characterized by mutations in TNAP associated with decreased enzyme activity in specific organs (10, 11) (Figure 1B). This decrease in AP activity results in variable symptoms that range from perinatal HPP that can result in still birth from profound skeletal hypomineralization (11, 12), potentially lethal seizures in infantile HPP (13–15), to milder phenotypes such as bone fractures and periodontal disease in juvenile HPP and adult HPP (16, 17). A relatively recent mouse model for HPP, in conjunction with medical data and genetic analysis has provided insight into the mechanism of HPP pathophysiology regarding at least two TNAP substrates, extracellular pyrophosphate (PPi), and pyridoxal-5-phosphate (PLP) (7).
Hypophosphatasia
Tissue non-specific AP is anchored to the cell membranes of osteoblasts and chondrocytes and to matrix vesicles released by those cells, where it degrades PPi to Pi. PPi is an inhibitor of mineralization (18) and regulation by TNAP controls propagation of extracellular mineralization of apatite crystals. TNAP deficiency increases the amount of inhibitory PPi thus decreasing extracellular mineralization, and humans with HPP show a loss of mineralization fronts (19). This has been recapitulated in a TNAP knockout mouse model for infantile HPP (20–22). The loss of mineralization results in various symptoms including softening of bone, bowing and spontaneous breakage of bones, rickets, and tooth (dentin/cementum/enamel) defects (23).
Pyridoxal-5-phosphate, the active form of vitamin B6 (24), is elevated in the serum of HPP patients (25, 26). Hydrolysis of PLP to pyridoxal (PL) by TNAP facilitates diffusion of PL across cell membranes, where it is then re-phosphorylated into PLP. PLP is a versatile cofactor for an estimated 4% of enzymatic reactions and is used by over 110 enzymes to produce or metabolize various molecules (27). PLP-dependent enzymes in the brain are responsible for the production of important neurochemicals including serotonin, dopamine, and gamma-aminobutyric acid (28). The decrease in PLP and resulting decrease in PLP-dependent metabolism in the brain in perinatal HPP patients has been implicated as the cause of neonatal seizures (29, 30).
Non-HPP TNAP Pathophysiology
Tissue non-specific AP has been implicated in non-HPP related medical conditions (Figure 1B). TNAP is expressed during embryonic neural and spinal chord development, and promotes axonal growth in vitro and neurogenesis in adults (31), suggesting an importance in proper neural function. Indeed, increased TNAP activity in the brain has been demonstrated in postmortem hippocampus and serum samples from Alzheimer’s disease patients and has been implicated in neuronal death through increased dephosphorylation of tau (32). Increased serum levels of AP (TNAP and/or TSAPs) due to mutations in GPI anchor synthesis, termed hyperphosphatasia, results most notably in Marby syndrome characterized by seizures, intellectual disability, and facial dysmorphology (33). TNAP upregulation in the vasculature contributes to medial vascular calcification causing vascular stiffening and eventually heart failure (34, 35). An emerging function for TNAP is regulation of purinergic signaling. Extracellular ATP and ADP, through the binding of nucleotide receptors, act as signals inducing inflammation after an acute event such as necrosis induced by damage or infection that releases intracellular nucleotides. In contrast, degradation of extracellular ATP and ADP to AMP and adenine causes cessation of inflammatory signaling, and induction through adenine receptors of an anti-inflammation response (36, 37). TNAP has been implicated in protection against inflammation in multiple diseases and promotion of intestinal microbial populations through hydrolysis of extracellular ATP/ADP to AMP and adenosine (38–40).
Intestinal AP
Intestinal AP is expressed in villus-associated enterocytes where it regulates fatty acid absorption through secretion of vesicles at both the luminal and basolateral surfaces (41, 42), regulates bicarbonate secretion and duodenal surface pH (43), and has been implicated in the regulation of diet-induced obesity (44, 45) and metabolic syndrome (46, 47) (Figure 1A). But perhaps, the most remarkable function of IAP centers on its protective interactions with the bacterial symbionts that inhabit or invade our enteric system. IAP has been shown to dephosphorylate (detoxify) the lipid A moiety of lipopolysaccharide (LPS), the outer lipid layer of the outer membrane of Gram-negative bacteria (48). In vertebrates, these phosphates are important for binding of LPS to the toll-like receptor 4/MD-2 innate immune receptor complex (49), initiation of NF-kB signaling, and immune response induction (50–52).
Intestinal AP deficiency has been associated with inflammation in the human intestine (53) and in the intestines of vertebrate models in which AP levels are decreased (54). Supplementation of IAP to animals where intestinal inflammation is induced directly or indirectly (with antibiotic use for example) reduces inflammation (53, 55, 56). In addition, a protective role has been ascribed to IAP in mouse models of necrotizing enterocolitis (57–59). This protective role may include IAP-dependent shaping (60) and homeostasis (61) of the microbiome. Along with direct regulation of intestinal homeostasis, IAPs and LPS detoxification have been implicated in other immune-related processes including prevention of bacterial translocation by endogenous or pharmacologically administered IAPs (62–64), and resolution of intestinal inflammation and tissue regeneration (65–67). It should also be noted that in addition to vertebrate IAP, TNAP has been shown to dephosphorylate LPS when it is applied to tissue sections from rat livers (68) and in the mouse uterus (69). With the current and increasing interest in the microbiome, IAP function as it relates to interaction with the endogenous microbes and its influence on human health will undoubtedly be clarified in the coming years.
Clinical Use of APs
Although there are a multitude of AP studies focusing on vertebrate models of disease, there are relatively few publications to date reporting pharmacological use of APs as a treatment in humans. At the time this article was written, a search of http://clinicaltrials.gov using AP as a search term produced over several hundred responses, however, the vast majority assay for AP levels in serum (a constant hazard when searching any science or medical database using “alkaline phosphatase” as a search term). However, there were at least 11 clinical trials concerning AP treatment of HPP, 3 concerning AP treatment of sepsis with renal injury or failure, 2 concerning AP treatment during or after cardiac surgery, and at least 1 each concerning AP treatment of rheumatoid arthritis, and ulcerative colitis (UC). Interestingly, these studies use several AP sources such as isolated bovine IAP (bIAP), recombinant bIAP, and recombinant human Aps (hAPs). AP enzyme replacement therapy is also currently available to treat HPP. A recombinant soluble human TNAP has been approved for use in perinatal, infantile, and juvenile-onset HPP (70, 71) and has proven successful in symptom improvement and survival in perinatal and infantile HPP (72, 73). In addition to HPP, use of AP as treatment increased renal function in sepsis-induced acute kidney injury (74, 75) and showed short-term improvement of severity of UC in patients with moderate-to-severe UC (76). These studies are a first glimpse into AP use as a treatment for disease, with very positive results. Given the jack of all trades nature of APs and the potential for APs as pharmacological agents in various diseases, studies like these should increase in the coming years.
Perspective
The ability of APs to detoxify LPS appears to be an evolutionarily conserved function as it was recently implicated in symbiont recognition and homeostasis in the invertebrate squid-Vibrio symbiosis model (77). As it is becoming clear that metazoans developed in a microbial world (78), it seems likely that APs have been and may continue to be an evolutionary force shaping the diversity and function of our endogenous microbial populations. Indeed, alterations in IAP have been shown to influence the composition of the intestinal microbiome (60). We can even expand this thinking—if hAPs evolved from an ancient ancestral bacterial AP, then APs may have had a prominent role in shaping basic human biochemistry in addition to our interactions with microbes, and thus exerted a profound influence on human health.
The reader of this review will notice that many of the articles cited might be considered old, with contributions from the 1960s, 1970s, and 1980s. In fact, the study of APs goes back close to 100 years when a bone enzyme freeing phosphate was first mentioned by Robison and Soames (79). That begs the question: how is it, after 90+ years, we still know relatively little about the overall functions of APs? The recent resurgence of interest in APs, should it continue, will hopefully provide more insight into all aspects of AP biology, especially as it relates to health. The ubiquity and functions of AP distinguish them as unconventional immune proteins, and to this writer, APs are unendingly fascinating.
Statements
Author contributions
BR solely contributed to the production of this manuscript.
Acknowledgments
This work was supported by NIH grant 1R15GM119100 to BR.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
GalperinMYKooninEVBairochA. A superfamily of metalloenzymes unifies phosphopentomutase and cofactor-independent phosphoglycerate mutase with alkaline phosphatases and sulfatases. Protein Sci (1998) 7:1829–35.10.1002/pro.5560070819
2
MillánJL. Mammalian Alkaline Phosphatases: From Biology to Applications in Medicine and Biotechnology. Weinheim: Wiley-VCH (2006).
3
LallèsJP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. Nutr Rev (2010) 68:323–32.10.1111/j.1753-4887.2010.00292.x
4
LallèsJ-P. Intestinal alkaline phosphatase: novel functions and protective effects. Nutr Rev (2014) 72:82–94.10.1111/nure.12082
5
ZimmermanAEMartinyACAllisonSD. Microdiversity of extracellular enzyme genes among sequenced prokaryotic genomes. ISME J (2013) 7:1187–99.10.1038/ismej.2012.176
6
YangYWandlerAMPostlethwaitJHGuilleminK. Dynamic evolution of the LPS-detoxifying enzyme intestinal alkaline phosphatase in zebrafish and other vertebrates. Front Immunol (2012) 3:314.10.3389/fimmu.2012.00314
7
BuchetRMillánJLMagneD. Multisystemic functions of alkaline phosphatases. Methods Mol Biol (2013) 1053:27–51.10.1007/978-1-62703-562-0_3
8
BermanHMWestbrookJFengZGillilandGBhatTNWeissigHet alThe protein databank. Nucleic Acids Res (2000) 28:235–42.10.1002/0470020571.ch10
9
StecBCheltsovAMillánJL. Refined structures of placental alkaline phosphatase show a consistent pattern of interactions at the peripheral site. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 66:866–70.10.1107/S1744309110019767
10
LinglartABiosse-DuplanM. Hypophosphatasia. Curr Osteoporos Rep (2016) 14:95–105.10.1007/s11914-016-0309-0
11
MornetE. Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene. Hum Mutat (2000) 15:309–15.10.1002/(SICI)1098-1004(200004)15:4<309:AID-HUMU2>3.0.CO;2-C
12
OlechEMZemojtelTSowińska-SeidlerARobinsonPNMundlosSKarczewskiMet alIdentification of a molecular defect in a stillborn fetus with perinatal lethal hypophosphatasia using a disease-associated genome sequencing approach. Pol J Pathol (2016) 67:78–83.10.5114/pjp.2016.59480
13
Baumgartner-SiglSHaberlandtEMummSScholl-BürgiSSergiCRyanLet alPyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T > C, p.M226T; c.1112C > T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone (2007) 40:1655–61.10.1016/j.bone.2007.01.020
14
NunesMLMugnolFBicaIFioriRM. Pyridoxine-dependent seizures associated with hypophosphatasia in a newborn. J Child Neurol (2002) 17:222–4.10.1177/088307380201700314
15
De RooMGAbelingNGMajoieCBBoschAMKoelmanJHCobbenJMet alInfantile hypophosphatasia without bone deformities presenting with severe pyridoxine-resistant seizures. Mol Genet Metab (2014) 111:404–7.10.1016/j.ymgme.2013.09.014
16
MoulinPVaysseFBiethEMornetEGenneroIDalicieux-LaurencinSet alHypophosphatasia may lead to bone fragility: don’t miss it. Eur J Pediatr (2009) 168:783–8.10.1007/s00431-008-0835-6
17
WeberTJSawyerEKMoseleySOdrljinTKishnaniPS. Burden of disease in adult patients with hypophosphatasia: results from patient-reported outcome surveys. Metabolism (2014) 65:1522–30.10.1016/j.metabol.2016.07.006
18
FleischHBisazS. Mechanism of calcification: inhibitory role of pyrophosphate. Nature (1962) 195:911.10.1038/195911a0
19
AndersonHCHsuHHMorrisDCFeddeKNWhyteMP. Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. Am J Pathol (1997) 151:1555–61.
20
GoldbergRFAustenWGZhangXMuneneGMostafaGBiswasSet alIntestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci U S A (2008) 105:3551–6.10.1073/pnas.0712140105
21
FeddeKNBlairLSilversteinJCoburnSPRyanLMWeinsteinRSet alAlkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res (1999) 14:2015–26.10.1359/jbmr.1999.14.12.2015
22
MillánJLYadavMSimaoANarisawaSHuesaCMcKeeMDet alLoss of bone mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function. Bone (2010) 46:S78.10.1016/j.bone.2010.01.191
23
MillánJL. The role of phosphatases in the initiation of skeletal mineralization. Calcif Tissue Int (2013) 93:299–306.10.1007/s00223-012-9672-8
24
ShidelerCE. Vitamin B6: an overview. Am J Med Technol (1983) 49:17–22.
25
WhyteMPMahurenJDVrabelLACoburnSP. Markedly increased circulating pyridoxal-5’-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest (1985) 76:752–6.10.1172/JCI112031
26
WhyteMPMahurenJDFeddeKNColeFSMcCabeERBCoburnSP. Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5’-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. J Clin Invest (1988) 81:1234–9.10.1172/JCI113440
27
PercudaniRPeracchiA. The B6 database: a tool for the description and classification of vitamin B6-dependent enzymatic activities and of the corresponding protein families. BMC Bioinformatics (2009) 10:273.10.1186/1471-2105-10-273
28
CruzTGleizesMBalayssacSMornetEMarsalGMillánJLet alIdentification of altered brain metabolites associated with TNAP activity in a mouse model of hypophosphatasia using untargeted NMR-based metabolomics analysis. J Neurochem (2017) 140:919–40.10.1111/jnc.13950
29
Sebastian-SerranoAEngelTde Diego-GarciaLOlivos-OreLAArribas-BlazquezMMartinez-FrailesCet alNeurodevelopmental alterations and seizures developed by mouse model of infantile hypophosphatasia are associated with purinergic signalling deregulation. Hum Mol Genet (2016) 1–14.10.1093/hmg/ddw248
30
BalasubramaniamSBowlingFCarpenterKEarlJChaitowJPittJet alPerinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5′-phosphate availability. J Inherit Metab Dis (2010) 33:S25–33.10.1007/s10545-009-9012-y
31
ZimmermannHLangerD. Tissue-nonspecific alkaline phosphatase in the developing brain and in adult neurogenesis. Subcell Biochem (2015) 76:61–84.10.1007/978-94-017-7197-9_4
32
KellettKABHooperNM. The role of tissue non-specific alkaline phosphatase (TNAP) in neurodegenerative diseases: Alzheimer’s disease in the focus. Subcell Biochem (2015) 76:363–74.10.1007/978-94-017-7197-9_17
33
ColeDECThompsonMD. Neurogenetic aspects of hyperphosphatasia in Mabry syndrome. Subcell Biochem (2015) 76:343–61.10.1007/978-94-017-7197-9_16
34
SheenCRKussPNarisawaSYadavMCNigroJWangWet alPathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. J Bone Miner Res (2015) 30:824–36.10.1002/jbmr.2420
35
SavinovAYSalehiMYadavMCRadichevIMillánJLSavinovaOV. Transgenic overexpression of tissue-nonspecific alkaline phosphatase (TNAP) in vascular endothelium results in generalized arterial calcification. J Am Heart Assoc (2015) 4.10.1161/JAHA.115.002499
36
IdzkoMFerrariDEltzschigHK. Nucleotide signalling during inflammation. Nature (2014) 509:310–7.10.1038/nature13085
37
CauwelsARoggeEVandendriesscheBShivaSBrouckaertP. Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis (2014) 5:e1102.10.1038/cddis.2014.70
38
MaloMSMoavenOMuhammadNBiswasBAlamSNEconomopoulosKPet alIntestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. Am J Physiol Gastrointest Liver Physiol (2014) 306:G826–38.10.1152/ajpgi.00357.2013
39
PetersEGeraciSHeemskerkSWilmerMJBilosAKraenzlinBet alAlkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate. Br J Pharmacol (2015) 172:4932–45.10.1111/bph.13261
40
DavidsonJAUrbanTTongSTwiteMWoodruffAWischmeyerPEet alAlkaline phosphatase, soluble extracellular adenine nucleotides, and adenosine production after infant cardiopulmonary bypass. PLoS One (2016) 11:e0158981.10.1371/journal.pone.0158981
41
MahmoodAEngleMJAlpersDH. Secreted intestinal surfactant-like particles interact with cell membranes and extracellular matrix proteins in rats. J Physiol (2002) 542:237–44.10.1113/jphysiol.2002.017087
42
McConnellREHigginbothamJNShifrinDATabbDLCoffeyRJTyskaMJ. The enterocyte microvillus is a vesicle-generating organelle. J Cell Biol (2009) 185:1285–98.10.1083/jcb.200902147
43
AkibaYMizumoriMGuthPHEngelEKaunitzJD. Duodenal brush border intestinal alkaline phosphatase activity affects bicarbonate secretion in rats. Am J Physiol Gastrointest Liver Physiol (2007) 293:G1223–33.10.1152/ajpgi.00313.2007
44
ŠefčíkováZHájekTLenhardtLRacekLMozesS. Different functional responsibility of the small intestine to high-fat/high-energy diet determined the expression of obesity-prone and obesity-resistant phenotypes in rats. Physiol Res (2008) 57:467–74.
45
Barbier de La SerreCEllisCLLeeJHartmanALRutledgeJCRaybouldHE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol (2010) 299(2):G440–8.10.1152/ajpgi.00098.2010
46
MaloMS. A high level of intestinal alkaline phosphatase is protective against type 2 diabetes mellitus irrespective of obesity. EBioMedicine (2015) 2:2016–23.10.1016/j.ebiom.2015.11.027
47
KaliannanKHamarnehSREconomopoulosKPNasrin AlamSMoavenOPatelPet alIntestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A (2013) 110:7003–8.10.1073/pnas.1220180110
48
BentalaHVerweijWRHuizinga-Van der VlagAvan Loenen-WeemaesAMMeijerDKFPoelstraK. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock (2002) 18:561–6.10.1097/01.shk.0000043623.17707.47
49
ParkBSSongDHKimHMChoiB-SLeeHLeeJ-O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 458:1191–5.10.1038/nature07830
50
HoshinoKTakeuchiOKawaiTSanjoHOgawaTTakedaYet alCutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 162:3749–52.10.1038/nri2275
51
AkiraSYamamotoM. Lipid a receptor TLR4-mediated signaling pathways. Adv Exp Med Biol (2009) 667:59–68.10.1007/978-1-4419-1603-7_6
52
BeutlerBRietschelET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol (2003) 3:169–76.10.1038/nri1004
53
TuinAPoelstraKde Jager-KrikkenABokLRaabenWVeldersMPet alRole of alkaline phosphatase in colitis in man and rats. Gut (2009) 58:379–87.10.1136/gut.2007.128868
54
BatesJMAkerlundJMittgeEGuilleminK. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe (2007) 2:371–82.10.1016/j.chom.2007.10.010
55
RamasamySNguyenDDEstonMANasrin AlamSMossAKEbrahimiFet alIntestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis (2011) 17:532–42.10.1002/ibd.21377
56
AlamSNYammineHMoavenOAhmedRMossAKBiswasBet alIntestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. Ann Surg (2014) 259:715–22.10.1097/SLA.0b013e31828fae14
57
HeinzerlingNPLiedelJLWelakSRFredrichKBiesterveldBEPritchardKAet alIntestinal alkaline phosphatase is protective to the preterm rat pup intestine. J Pediatr Surg (2014) 49:954–60; discussion 960.10.1016/j.jpedsurg.2014.01.031
58
RenteaRMLiedelJLWelakSRCassidyLDMayerANPritchardKAet alIntestinal alkaline phosphatase administration in newborns is protective of gut barrier function in a neonatal necrotizing enterocolitis rat model. J Pediatr Surg (2012) 47(6):1135–41.10.1016/j.jpedsurg.2012.03.018
59
BiesterveldBEKoehlerSMHeinzerlingNPRenteaRMFredrichKWelakSRet alIntestinal alkaline phosphatase to treat necrotizing enterocolitis. J Surg Res (2015) 196:235–40.10.1016/j.jss.2015.02.030
60
FawleyJKoehlerSCabreraSLamVFredrichKHessnerMet alIntestinal alkaline phosphatase deficiency leads to dysbiosis and bacterial translocation in the newborn intestine. J Surg Res (2017) 218:35–42.10.1016/j.jss.2017.03.049
61
MaloMSAlamSNMostafaGZellerSJJohnsonPVMohammadNet alIntestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut (2010) 59:1476–84.10.1136/gut.2010.211706
62
ShifrinDAMcConnellRENambiarRHigginbothamJNCoffeyRJTyskaMJ. Enterocyte microvillus-derived vesicles detoxify bacterial products and regulate epithelial-microbial interactions. Curr Biol (2012) 22:627–31.10.1016/j.cub.2012.02.022
63
Martínez-MoyaPOrtega-GonzálezMGonzálezRAnzolaAOcónBHernández-ChirlaqueCet alExogenous alkaline phosphatase treatment complements endogenous enzyme protection in colonic inflammation and reduces bacterial translocation in rats. Pharmacol Res (2012) 66:144–53.10.1016/j.phrs.2012.04.006
64
WangWChenSWZhuJZuoSMaYYChenZYet alIntestinal alkaline phosphatase inhibits the translocation of bacteria of gut-origin in mice with peritonitis: mechanism of action. PLoS One (2015) 10:e0124835.10.1371/journal.pone.0124835
65
YagiMSakamotoKInoueTFukushimaWHashimotoTShimizuKet alEffect of glutamine-enriched, elemental diet on regeneration of residual small bowel mucosa and hepatic steatosis following massive bowel resection. J Clin Biochem Nutr (1993) 15:219–25.10.3164/jcbn.15.219
66
CampbellELMacmanusCFKominskyDJKeelySGloverLEBowersBEet alResolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci U S A (2010) 107:14303.10.1073/pnas.0914730107
67
LiuWHuDHuoHZhangWAdiliaghdamFMorrisonSet alIntestinal alkaline phosphatase regulates tight junction protein levels. J Am Coll Surg (2016) 222:1009–17.10.1016/j.jamcollsurg.2015.12.006
68
PoelstraKBakkerWWKlokPAKampsJAHardonkMJMeijerDK. Dephosphorylation of endotoxin by alkaline phosphatase in vivo. Am J Pathol (1997) 151:1163–9.
69
LeiWNiHHeringtonJReeseJPariaBC. Alkaline phosphatase protects lipopolysaccharide-induced early pregnancy defects in mice. PLoS One (2015) 10:e0123243.10.1371/journal.pone.0123243
70
Bloch-ZupanA. Hypophosphatasia: diagnosis and clinical signs – a dental surgeon perspective. Int J Paediatr Dent (2016) 26(6):426–38.10.1111/ipd.12232
71
OrimoH. Pathophysiology of hypophosphatasia and the potential role of asfotase alfa. Ther Clin Risk Manag (2016) 12:777–86.10.2147/TCRM.S87956
72
WhyteMPRockman-GreenbergCOzonoKRieseRMoseleySMelianAet alAsfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab (2016) 101:334–42.10.1210/jc.2015-3462
73
HofmannCSeefriedLJakobF. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Drugs Today (Barc) (2016) 52:271–85.10.1358/dot.2016.52.5.2482878
74
PetersEvan ElsasAHeemskerkSJonkLvan der HoevenJArendJet alAlkaline phosphatase as a treatment of sepsis-associated acute kidney injury. J Pharmacol Exp Ther (2013) 344:2–7.10.1124/jpet.112.198226
75
HeemskerkSMasereeuwRMoeskerOBouwMPvan der HoevenJGPetersWHet alAlkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med (2009) 37:417–423,e1.10.1097/CCM.0b013e31819598af
76
LukasMDrastichPKonecnyMGionchettiPUrbanOCantoniFet alExogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. Inflamm Bowel Dis (2010) 16:1180–6.10.1002/ibd.21161
77
RaderBAKremerNApicellaMAGoldmanWEMcFall-NgaiMJ. Modulation of symbiont lipid a signaling by host alkaline phosphatases in the squid-vibrio symbiosis. MBio (2012) 3.10.1128/mBio.00093-12
78
McFall-NgaiMHadfieldMGBoschTCGCareyHVDomazet-LošoTDouglasAEet alAnimals in a bacterial world, a new imperative for the life sciences. Proc Natl Acad Sci U S A (2013) 110:3229–36.10.1073/pnas.1218525110
79
RobisonRSoamesKM. The possible significance of hexosephosphoric esters in ossification. Biochem J (1924) 18:740–54.10.1097/00003086-199106000-00001
Summary
Keywords
alkaline phosphatase, hypophosphatasia, tissue non-specific AP, intestinal AP, lipopolysaccharide, microbiome
Citation
Rader BA (2017) Alkaline Phosphatase, an Unconventional Immune Protein. Front. Immunol. 8:897. doi: 10.3389/fimmu.2017.00897
Received
24 May 2017
Accepted
13 July 2017
Published
03 August 2017
Volume
8 - 2017
Edited by
Larry J. Dishaw, University of South Florida St. Petersburg, United States
Reviewed by
Alain Couvineau, Institut national de la santé et de la recherche médicale, France; Elmar Pieterse, Radboud University Nijmegen Medical Center, Netherlands
Updates
Copyright
© 2017 Rader.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bethany A. Rader, bethany.rader@siu.edu
Specialty section: This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.